Anti-Idiopathic pulmonary fibrosis emerges as an important public health disturbance globally that is serving as increased emphasis on novel drug innovations in the market
Meridian Market Consultants (MMC) has published a
new report titled, “Anti-Idiopathic Pulmonary Fibrosis Drugs Market:
Opportunity Analysis and Future Assessment 2019 to 2027”
Global
Anti-Idiopathic Pulmonary Fibrosis Drugs Market Overview
An overview of conceptual frameworks,
analytical approaches of the Anti-Idiopathic Pulmonary Fibrosis
Drugs Market is the main objective of the report, which further
consists the market opportunity and insights of the data involved in the making
of the respective market. Anti-Idiopathic Pulmonary Fibrosis Drugs Market is
expected to grow with significant rate in the near future.
MMC Overview
The non-identical approach of Meridian Market
Consultants stands with conceptual methods backed up with the data analysis.
The novel market understanding approach makes up the standard of the assessment
results that give better opportunity for the customers to put their effort.
Request to View Sample of Report: https://www.meridianmarketconsultants.com/requst?rid=6954
Global
Anti-Idiopathic Pulmonary Fibrosis Drugs Market Dynamics
Growing
prevalence of idiopathic pulmonary fibrosis (IPF), coupled with increasing
geriatric population across the globe are major factors that are expected to
drive the growth of the global anti-idiopathic pulmonary fibrosis drugs market
during the forecast period. For instance, according to the World Population
Aging Report 2015 by United Nations, total population aged 60 years and above
is expected to grow by 56%, i.e., from 901 Mn in 2015 to 1.4 Bn in 2030. Also,
commercialization of novel drugs is another important factor boosting growth of
the target market. Furthermore, surge in cigarette smoking population is
expected to propel the growth of the market in the near future. Moreover,
presence of strong pipeline provided by the government for the treatment is
likely to increase the growth of global anti-idiopathic pulmonary fibrosis
drugs market. However, unknown disease etiology, there is no specific cure for
idiopathic pulmonary fibrosis, which is restraining the growth of the target
market.
Global
Anti-Idiopathic Pulmonary Fibrosis Drugs Market
Segmentation
Anti-idiopathic pulmonary fibrosis drugs
market is segmented on the basis of market drugs, mechanism of action,
innovator and off-label drugs, and by region.
·
By Marketed Drugs:
Ø Esbriet
Ø Ofev
·
By Mechanism of Action:
Ø Antifibrotics
Ø Tyrosine Kinase Inhibitors
Ø Anti-Inflammatory Drugs
Ø Immunosuppressant’s
Ø Others
·
By Innovator and Off-Label Drugs:
Ø Innovator Drugs
Ø Off-Label Drugs
·
By Region:
Ø North America
Ø Europe
Ø Asia Pacific
Ø Latin America
Ø Middle East
Ø Africa
Global
Anti-Idiopathic Pulmonary Fibrosis Drugs Market Overview
More than 200 diseases related to lungs are mainly
belongs to Idiopathic pulmonary fibrosis (IPF) which is known as interstitial
lung diseases (ILDs), which is characterized by the involvement of the tissues which
are found in between air sacs of the lung also known as lung interstitium. IPF
is one specific presentation of idiopathic interstitial pneumonia (IIP), which
is in turn a type of ILD, also called diffuse parenchymal lung disease (DPLD). Idiopathic
pulmonary fibrosis (IPF) is a progressive disease in which lungs get affected
and gets scars and marks in tissues and affect lungs performance in a negative
manner. Persistent non-productive cough and dyspnea are most common symptoms
and signs of idiopathic pulmonary fibrosis. Also, gradual weight loss and loss
of appetite is also found in many individuals due to the idiopathic pulmonary
fibrosis. IPF mainly occurs in older adults. However, the causes are unknown.
It has been noted that idiopathic pulmonary fibrosis is prevailing more in
smoking population. People also suffer from lung diseases due to second hand
smoking which is the smoke that fills restaurants, offices or other enclosed
spaces when people burn tobacco products such as cigarettes, bidis and
water-pipes. According to study done by WHO, in May 2019, In adults,
second-hand smoke causes serious cardiovascular and respiratory diseases,
including coronary heart disease and lung cancer. In infants, it raises the
risk of sudden infant death syndrome. In pregnant women, it causes pregnancy
complications and low birth weight. Second-hand smoke causes more than 1.2 million
premature deaths per year. Also more than 65,000 children die every year from
illnesses attributable to second-hand smoke.
Global
Anti-Idiopathic Pulmonary Fibrosis Drugs Market Competitive Landscape
Some of the key participating players in anti-idiopathic
pulmonary fibrosis drugs market are Actelion, Afferent Pharmaceuticals, Asahi
Kasei Pharma, Bellerophon Therapeutics, Biogen, Boehringer Ingelheim, FibroGen,
Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, and Kadmon
Pharmaceuticals and others.
Regional Segmentation:
On the basis of region, the anti-idiopathic
pulmonary fibrosis drugs market is segmented into North America, Europe, Asia
Pacific, Latin America, Middle East, and Africa.
Contact Us
Meridian Market Consultants
13121, Louetta Road,
#440, Cypress, Texas 77429
United States
Tel: +1-(281)-619-8646
For More Info: Info@meridianmarketconsultants.com
Website:
http://www.meridianmarketconsultants.com
Comments
Post a Comment